Update on follicular lymphoma.
Update on follicular lymphoma.
复制标题
滤泡性淋巴瘤的最新进展。
DOI：
10.1002/hon.3138
复制
发表时间：
2023
影响因子：
3.3
通讯作者：
Friedberg,JonathanW
中科院分区：
文献类型：
--
作者：
Friedberg,JonathanW
在过去的二十年中已经看到了滤泡性淋巴瘤的生物学理解和优化治疗显着进步。历史上被认为是一种不治之症，对几种诱导方法的长期随访表明，高达40%的患者缓解持续时间为10年或更长，死于淋巴瘤的风险继续下降。本次更新将重点关注滤泡性淋巴瘤在过去3年中的进展，其中包括分期和预后的改进，复发性和难治性疾病的新型免疫治疗方法，以及关键试验的长期随访。正在进行的试验将确定这些新治疗的最佳顺序，包括早期结合这些方法是否可能导致这种疾病的最终治愈。通过正在进行的和计划的相关研究，我们准备最终实现一个精确的管理方法滤泡性淋巴瘤的目标.
The past two decades have seen remarkable progress in both biological understanding and optimizing treatment of follicular lymphoma. Historically considered an incurable disease, long‐term follow‐up of several induction approaches demonstrates that up to 40% of patients enjoy remission durations of 10 or more years, and risk of dying of lymphoma continues to fall. This update will focus on progress in follicular lymphoma over the past 3 years, which has included refinements in staging and prognosis, novel immunotherapy treatment approaches for relapsed and refractory disease, and long‐term follow‐up of pivotal trials. Ongoing trials will define the optimal sequence for these novel treatments, including whether earlier incorporation of these approaches may result in definitive cure of this disease. Through ongoing and planned correlative studies, we are poised to ultimately achieve the goal of a precision management approach to follicular lymphoma.